COVID-19 Evidence Review Group for Medicines
The COVID-19 Evidence Review Group for Medicines was established to support the HSE in managing the significant amount of information on treatments for COVID-19. This COVID-19 Evidence Review Group is comprised of evidence synthesis practitioners from across the National Centre for Pharmacoeconomics (NCPE), Medicines Management Programme (MMP) and the National Medicines Information Centre (NMIC). The group respond to queries raised via the Office of the Chief Clinical Officer, National Clinical Programmes and the Department of Health and respond in a timely way with the evidence review supporting the query.
In order to provide timely information to decision makers a rapid evidence review is the chosen methodology. The Evidence Review Group uses a systematic search strategy that searches for both peer reviewed and non-peer reviewed publications. The Rapid Evidence Reviews are updated frequently (1-2 weeks) depending on the topic of the review.
Rapid Evidence Reviews
ERG RER for Neutralising Monoclonal Antibodies for COVID-19 Latest update 26 November 2021
Antivirals for treatment of COVID-19 A Rapid Evidence Review Version 15 Latest Update 27 August 2021
Search Strategy for Evidence Reviews in COVID-19 Latest Update 27 August 2020
Hydroxychloroquine in combination with azithromycin for the treatment of COVID-19: A Rapid Evidence Review Latest Update 17 April 2020
Tocilizumab in the management of COVID-19: A Rapid Evidence Review Latest Update 25 February 2021
Intravenous immunoglobulin for the treatment of COVID-19: A Rapid Evidence Review Latest Update 19 February 2021
Thromboprophylaxis in patients with COVID-19: A Rapid Evidence Review Latest Update 22 March 2021